WEDNESDAY, Feb. 26, 2020 -- For patients with untreated stage II or III triple-negative breast cancer, pembrolizumab plus neoadjuvant chemotherapy, compared with placebo plus neoadjuvant chemotherapy, is associated with a significantly higher rate...
Original Article: Adding Pembrolizumab May Up Response in Triple-Negative Breast Cancer